Sign in
Taking people in United StatesPhase 1/2

Atomoxetine combined with DAW2022 for obstructive sleep apnea

Tests atomoxetine with DAW2022 to lower obstructive sleep apnea severity in adults.

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Atomoxetine and DAW2022 on OSA Severity
Status
Recruiting
Phase
Phase 1/2
People taking part
18 people, planned
Started
1 Jun 2022
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Placebo oral capsule
  • Atomoxetine Oral Capsule [Strattera]
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate to severe obstructive sleep apnea, where breathing stops again and again during sleep. It tests atomoxetine with DAW2020 against a placebo (dummy pill).

Age
21 Years to 70 Years
Sex
All sexes can join
Disease stage
Moderate to severe obstructive sleep apnea (AHI ≥ 15 events/hr, meaning at least 15 breathing pauses or drops per hour of sleep)
Earlier treatment
People who use medicines that speed up or slow down breathing (such as opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid) cannot join. People who use SNRIs/SSRIs, or medicines that lengthen the QTc interval (a heart rhythm measure), cannot join.

Main reasons for not taking part

  • Major organ disease, nerve or muscle disease, heart failure, or another unstable major illness
  • Breathing problems during sleep, or lung problems, other than obstructive sleep apnea
  • Other sleep disorders: periodic limb movements (arousal index > 10/hr), narcolepsy or parasomnias
  • Allergy to the study drug (angioedema or urticaria), or reasons not to take DAW2020
  • Low potassium, low magnesium, uncontrolled thyroid disease, or severe claustrophobia

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Who cannot take part

  • Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid)
  • All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements
  • Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition
  • Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
  • Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias
  • Hypersensitivity to the study drug (angioedema or urticaria)
  • Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
  • Use of medications that lengthen QTc interval
  • Use of SNRIs/SSRIs
  • Contraindications to DAW2020
  • Severe claustrophobia

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 70 years old?

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Nicole CalianeseTaking people

About the trial

What the trial wants to find out

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.

The 2 groups in the trial

  • Placebo oral capsulesPlacebo, for comparison

    Placebo (2 pills) before sleep for a week

    Treatment: Placebo oral capsule

  • Atomoxetine and DAW2020 oral capsulesExisting treatment, for comparison

    DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep

    Treatment: Atomoxetine Oral Capsule [Strattera]

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Atomoxetine and DAW2022 on OSA Severity
Plain-language title
Atomoxetine combined with DAW2022 for obstructive sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05350215, who can take part
Publications
Record updated
10 July 2026